Abivax S.a.

This study tested an experimental daily pill called ABX464 in 355 adults with moderate to severe ulcerative colitis who had not responded well to other treatments. The goal was to see if the drug could reduce symptoms like diarrhea, bleeding, and colon inflammation compared to a …

This study looked at the long-term safety and effectiveness of a drug called ABX464 in 40 people with moderate to severe rheumatoid arthritis. Participants took a 50mg daily dose as maintenance therapy after completing an initial 12-week treatment. The goal was to see if the drug…

This study tested a new drug called ABX464 in 639 people with moderate to severe ulcerative colitis who had not responded well to other treatments. Participants took either 25 mg, 50 mg, or a placebo pill once daily for 8 weeks. The main goal was to see if the drug could help ach…

This study tested a new daily medication, ABX464, in 636 people with moderate to severe ulcerative colitis who had not responded well to other treatments. The goal was to see if the drug could help achieve remission (symptom relief and healing of the colon) after 8 weeks. The stu…

This study tested a daily pill called ABX464 in 217 adults with moderate to severe ulcerative colitis who had already completed 16 weeks of treatment. The goal was to see if the drug could keep the disease in remission for up to 96 weeks. The approach focuses on controlling the d…